The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Anaphylaxis-Anaphylactoid reaction (can be fatal)
Publications
Touraine F, Sainte Laudy J, Boumediene A, Ndikumwenayo F, Decroisette C, Melloni B, Vergnenegre A, Bonnaud F
[Investigation of allergic reactions to platinum salts].
Revue des maladies respiratoires. 2006;23(5 Pt 1):458-62
Anaphylaxis to cisplatin following nine previous uncomplicated cycles.
International journal of clinical oncology. 2002;7(6):365-7
Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles.
American journal of clinical oncology. 1997;20(4):373-5
Death from anaphylaxis to cisplatin: a case report.
Gynecologic oncology. 1994;53(1):121-2
Atopic hypersensitivity to cis-dichlorodiammineplatinum(II) and other platinum complexes.
Cancer research. 1975;35(10):2766-70